Evaluation of trazodone and quetiapine in patients with Alzheimer's type dementia and sleep disturbance

Petrescu, B.M.; Vasile, D.; Vasiliu, O.; Mangalagiu, A.G.; Riga, Danai; Riga, Sorin; Mitrache, Alina; Simioniuc-Petrescu, Anca

doi:10.1016/j.euroneuro.2018.11.274

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…other comorbidities due to inability or lack of willing-taking trazodone (50-200 mg) had more total sleep time in both patient-and nurse-reported measures, although it was associated with more side effects than quetiapine [60]. Interestingly, trazodone may have a possible neuroprotective effect in AD patients with insomnia; a retrospective study by La et al…”

Section: U N C O R R E C T E D a U T H O R P R O O Fmentioning

confidence: 99%

Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer’s Disease: A Structured Literature Review

Benca

Herring

Khandker

et al. 2022

JAD

View full text Add to dashboard Cite

Background: Sleep disturbances are frequent in Alzheimer’s disease (AD). This review summarizes the impact of sleep disturbances on AD patients and their caregivers and the effects of currently available sleep therapies. Methods: Published studies (January 1985–March 2020) assessing the burden associated with insomnia/sleep disturbances in the AD population and insomnia treatment effects were identified by searching PubMed, Embase and Cochrane Library and screened against inclusion criteria. Findings: This review included 58 studies which assessed patient and caregiver burden, institutionalization, and insomnia treatments in AD patients with sleep disturbances. Sleep disturbances were associated with worse cognition, functional ability, and behavioral and neuropsychological functioning, including increased depression and anxiety. Health status and quality of life of both patients and caregivers were reduced in the presence of sleep disturbances, with caregiver burden driven largely by disruptive nocturnal behaviors including nighttime awakenings and wanderings. Sleep disturbances were also associated with institutionalization. Although significant associations between sleep problems and clinical outcomes were apparent, there was generally no control for other influencing factors (e.g. cognitive status). With respect to insomnia treatments, bright light, and behavioral therapies as well as drugs such as trazodone, risperidone and suvorexant showed some promise in AD patients, but studies were primarily small and limited data were available, particularly in regard to insomnia treatment effects on associated clinical burden. Interpretation: Sleep disturbances are a significant problem for AD patients and caregivers. They are associated with behavioral and psychological problems and cognitive decline and impose a burden on caregivers, but remain poorly characterized and under-researched. As the global population is aging and AD is on the rise, data from larger, prospective trials are required to fully understand the clinical correlates of sleep disturbances and the impact of insomnia treatments on AD patients and their caregivers.

show abstract

Section: U N C O R R E C T E D a U T H O R P R O O Fmentioning

confidence: 99%